New Delhi, Sept. 26 -- Continuing his policy of imposing tariffs on imports, US President Donald Trump on Thursday announced 100% duties on branded drugs from 1 October. The move is unlikely to impact India, as the country is a major player in generic medicines and vaccines. Nevertheless, the decision has caused jitters.According to a report by Brickwork Research, innovator or branded drugs make up only about 3-4% of India's formulation market. It is the branded generic products that take the lion's share. This trend has been consistent over the years.







"Given the duties announced are on branded/patented drugs, there would be no impact on the generics exports done by Indian pharma companies," said Tushar Manudhane, senior vice presi...